Literature DB >> 24192676

Infectious complications and conservative treatment of totally implantable venous access devices in children with cancer.

Nalan Yazıcı1, Canan Akyüz, Bilgehan Yalçın, Ali Varan, Tezer Kutluk, Münevver Büyükpamukçu.   

Abstract

Besides their complications, totally implantable venous access devices (TIVADs) increase the quality of life in children with cancer. The aim of this study was analysis of infectious complications and results of conservative management in TIVADs. Three hundred and one catheters were implanted in 283 patients between February 1991 and January 2005. Infectious complications were analyzed retrospectively. Cumulative duration of implantation was 153,757 days. In 140 devices (46.5%), no complication was detected. Total rate of infection was 1.96/1000 catheter days. Types of infections were as follows: catheterrelated bloodstream infections: 190; catheter-related systemic infections: 74; pocket infections: 19, exit site infections: 14; and tunnel infections: 5. Staphylococcus epidermidis and non-albicans candida were the most common isolations. During follow-up, a total of 119 catheters had been removed. Most of them were due to infection (n=42). In conclusion, TIVADs are important in children with cancer who need prolonged intravenous access, so they should be used carefully and managed conservatively in case of complications.

Entities:  

Mesh:

Year:  2013        PMID: 24192676

Source DB:  PubMed          Journal:  Turk J Pediatr        ISSN: 0041-4301            Impact factor:   0.552


  2 in total

1.  Cohort Study: Central Venous Catheter-Related Complications in Children with Hematologic Diseases at a Single Center.

Authors:  Ayhan Pektaş; Ateş Kara; Aytemiz Gurgey
Journal:  Turk J Haematol       Date:  2015-06       Impact factor: 1.831

2.  Transesophageal echocardiography-guided implantation of totally implantable venous access devices via the internal jugular vein: retrospective analysis of 297 cases in pediatric patients.

Authors:  Yuanzhen Chen; Dajun Xing; Lixin Wu; Huatian Lin; Ting Lin; Fang Ding; Liang Xu
Journal:  World J Surg Oncol       Date:  2022-08-30       Impact factor: 3.253

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.